Sotrovimab for COVID-19

1	
2	
3	Sotrovimab versus usual care in patients admitted to
4	hospital with COVID-19: a randomised, controlled,
5	open-label, platform trial (RECOVERY)
6	
7	Running title: Sotrovimab for patients hospitalised with COVID-19
8	RECOVERY Collaborative Group*
9	
10	
11	*The writing committee and trial steering committee are listed at the end of this
12	manuscript and a complete list of collaborators in the Randomised Evaluation of
13	COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix.
14	
15	Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central
16	Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3
17	7LF, United Kingdom.
18	Email: recoverytrial@ndph.ox.ac.uk

Sotrovimab for COVID-19

20 SUMMARY

Background: Sotrovimab is a neutralising monoclonal antibody that has been proposed
as a treatment for patients admitted to hospital with COVID-19.

Methods: In this randomised, controlled, open-label platform trial, several possible 23 24 treatments were compared with usual care in patients hospitalised with COVID-19 25 pneumonia. In the sotrovimab comparison, eligible and consenting patients were 26 randomly allocated to either usual care alone or usual care plus a single 1g dose of 27 sotrovimab, using web-based unstratified randomisation. Participants were 28 retrospectively categorised according to their baseline serum SARS-CoV-2 nucleocapsid 29 antigen concentration as 'high-antigen' or 'low-antigen', using the median concentration 30 as a cut-off. The primary outcome was 28-day mortality assessed by intention to treat. 31 Secondary outcomes were time to discharge alive from hospital, and, among those not 32 on invasive ventilation at baseline, progression to invasive ventilation or death. 33 Recruitment closed on 31 March 2024 when funding ended. ISRCTN (50189673) and 34 clinicaltrials.gov (NCT04381936).

Findings: From 4 January 2022 to 19 March 2024, 1723 patients were recruited to the sotrovimab comparison. 720 (42%) were classified as high-antigen, 717 (42%) as lowantigen, and 286 (17%) had unknown antigen status. Over 80% of patients were vaccinated, over 80% had anti-spike antibodies at randomisation, and almost all were infected with Omicron variants. In the prespecified primary efficacy population of highantigen patients, 82/355 (23%) allocated sotrovimab versus 106/365 (29%) allocated usual care died within 28 days (rate ratio 0.75; 95% CI 0.56-0.99; p=0.046). In an analysis

Sotrovimab for COVID-19

42	of all randomised	patients	(regar	dless o	of	antigen	statu	us),	177/82	28	(21%)	alloc	ated
43	sotrovimab versus	201/895	(22%)	allocat	ed	usual o	care o	died	within	28	days	(rate	ratio
44	0.95; 95% CI 0.77-	1.16; p=0	.60).										

- 45 Interpretation: In patients hospitalised with COVID-19, sotrovimab was associated with
- 46 reduced mortality in the primary analysis population of patients with a high serum SARS-
- 47 CoV-2 antigen concentration at baseline, but not in the overall population.
- 48 **Funding:** UK Research and Innovation (Medical Research Council) and National Institute
- 49 of Health Research (Grant ref: MC_PC_19056).
- 50 **Keywords:** COVID-19, sotrovimab, monoclonal antibody, clinical trial.

Sotrovimab for COVID-19

52 **INTRODUCTION**

53 Treatment with neutralising monoclonal antibodies (mAbs) targeting the SARS-CoV-2 spike protein has been found to substantially reduce the risk of hospitalisation or death in 54 patients with early COVID-19 who are at high risk of complications.^{1–3} nMAbs were also 55 found to reduce the risk of death among hospitalised patients, but this benefit was 56 57 restricted to those who had not yet developed their own anti-SARS-CoV-2 antibody response (i.e. who are seronegative).^{4–6} The RECOVERY casirivimab-imdevimab 58 comparison, which recruited UK patients from September 2020 to May 2021 is the largest 59 randomised evaluation of mAb therapy in hospitalised patients. In this comparison, 28-60 61 day mortality in patients who were seronegative at randomisation was double that of seropositive patients (30% versus 15%), and mAb therapy reduced this to 24% (rate ratio 62 63 0.79; 95% confidence interval 0.69-0.91; p=0.0009; number of seronegative patients 64 treated to save one life = 16).⁴ Following this, targeted mAb therapy for seronegative 65 patients hospitalised with COVID-19 was adopted into routine practice in the UK and elsewhere. 66

A major limitation of mAb therapy has been the frequent emergence of new SARS-CoVvariants that are not effectively neutralised by existing antibodies.^{7,8} When the first Omicron variant, BA.1, became globally dominant in December 2021, it contained spike mutations conferring high-level resistance to most mAbs in clinical use.⁸ This included the casirivimab-imdevimab combination, leading to its withdrawal from guidelines. Sotrovimab, a mAb originally developed from an antibody recovered from a patient who had recovered from SARS-CoV-1, targets a relatively conserved spike protein epitope,

Sotrovimab for COVID-19

74 and in the COMET-ICE trial of patients with early infection conducted in 2020-21 it reduced the risk of hospitalisation or death by 79%.¹ The neutralisation potency of 75 sotrovimab was modestly reduced against BA.1 (~3-5-fold) compared to wild-type virus, 76 77 but it retained more activity than many other mAbs, which made it a promising candidate for continued use in hospitalised patients and prompted its evaluation in RECOVERY.^{9,10} 78 79 A further reduction in activity against BA.2 led to the withdrawal of FDA Emergency Use Authorization in the U.S. for sotrovimab in April 2022. However, it retained enough in vitro 80 activity against viral variants prevalent in 2022-23 to suggest it could retain clinical benefit, 81 either via direct neutralisation or via Fc-dependent effector mechanisms.^{11,12} During 82 November 2023, BA.2.86 and JN.1 SARS-CoV-2 variants became dominant in the UK 83 84 and elsewhere, which have an additional spike gene mutation that confers high-level 85 resistance to sotrovimab.¹³

86 The current role of therapeutic neutralising mAbs in hospitalised patients is also complicated by increasing population immunity to SARS-CoV-2, as the previous trials that 87 88 identified a benefit in seronegative patients were performed before widespread 89 vaccination and natural immunity. By the time the Omicron BA.1 variant emerged, most people hospitalised in the UK with COVID-19 had been vaccinated and many had had 90 91 previous infection. In this setting, patients would be expected to have detectable anti-92 SARS-CoV-2 antibodies at admission, but this could reflect immune responses to 93 previous vaccination or infection that had failed to prevent the current illness, rather than 94 adaptive immunity to the current infection. This suggests that alternative biomarkers of 95 infection status may now be required to identify which, if any, hospitalised patients could benefit from mAb treatment. 96

Sotrovimab for COVID-19

97 One possible biomarker is SARS-CoV-2 antigenaemia. Viral nucleocapsid antigen is 98 detectable in the blood of most hospitalised patients, and high concentrations are strongly 99 correlated with more severe disease and worse prognosis.^{14–16} In most hospitalised 100 patients, antigen levels fall rapidly in the first few days of admission as the infection is 101 cleared.¹⁷ The degree of antigenaemia is inversely correlated with specific antibody 102 responses, but, unlike antibodies, detection of viral antigen almost certainly relates only 103 to the current infection.

Here we report the results of the sotrovimab comparison in RECOVERY, a randomised, open-label platform trial evaluating treatments for patients hospitalised with COVID-19 pneumonia. Recruitment occurred in the UK in a period in which Omicron variants were dominant and most people were vaccinated against SARS-CoV-2. The prespecified primary analysis population was patients who had serum SARS-CoV-2 nucleocapsid antigen concentration at randomisation that was above the median value of all trial participants in this comparison.

111 METHODS

112 Study design and participants

The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigatorinitiated, individually randomised, controlled, open-label, adaptive platform trial to evaluate the effects of potential treatments in patients hospitalised with COVID-19. Details of the trial design and results for other treatments have been published previously and are available at <u>www.recoverytrial.net/results</u>.^{4,18–28} The trial was conducted at hospital organisations in the United Kingdom and supported by the National Institute for

Sotrovimab for COVID-19

119 Health and Care Research Clinical Research Network. 107 hospitals in the UK enrolled 120 participants in the sotrovimab comparison (appendix pp5-32). The trial is coordinated by 121 the Nuffield Department of Population Health at the University of Oxford (Oxford, UK), the 122 trial sponsor, and is conducted in accordance with the principles of the International 123 Conference on Harmonisation–Good Clinical Practice guidelines and is approved by the 124 UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Cambridge 125 East Research Ethics Committee (ref: 20/EE/0101). The protocol, statistical analysis plan, 126 and additional information are available in the appendix (pp70-186) and on the study 127 website www.recoverytrial.net.

Patients admitted to hospital were eligible for the study if they had confirmed SARS-CoV-2 infection with a pneumonia syndrome thought to be related to COVID-19, and no medical history that might, in the opinion of the managing physician, put the patient at significant risk if they were to participate in the trial. Patients were excluded if they were aged <12 years or were aged <18 years and weighed <40kg. Pregnant women were eligible. Written informed consent was obtained from all patients, or a legal representative if patients were too unwell or otherwise unable to provide informed consent.

135 Randomisation and masking

Eligible and consenting patients were randomly assigned in a 1:1 ratio to either usual standard of care plus sotrovimab or usual standard of care alone, using web-based simple (unstratified) randomisation with allocation concealed until after randomisation (appendix pp42-44). Patients allocated to sotrovimab were to receive 1g in 100ml 0.9% saline or 5% glucose intravenously over 60 minutes as soon as possible after randomisation. This is

Sotrovimab for COVID-19

double the licensed dose for early infection and was selected because of reducedneutralisation activity against Omicron BA.1 compared to wild-type virus.

143 As a platform trial, and in a factorial design, patients could be simultaneously included in 144 other concurrently evaluated treatment comparisons, each having its allocation 145 determined by an independent 1:1 randomisation: (i) empagliflozin versus usual care, (ii) 146 higher-dose corticosteroids versus usual care, (iii) molnupiravir versus usual care, and 147 (iv) nirmatrelvir-ritonavir versus usual care (appendix pp42-43). Participants and local 148 study staff were not masked to allocated treatment. Other than members of the Data 149 Monitoring Committee, all individuals involved in the trial were masked to aggregated 150 outcome data while recruitment and 28-day follow-up were ongoing.

151 **Procedures**

152 Baseline data were collected using a web-based case report form that included 153 demographics, level of respiratory support, major comorbidities, suitability of the study 154 treatment for a particular patient, SARS-CoV-2 vaccination status, and study treatment 155 availability at the study site (appendix pp47). A serum sample and nose swab were 156 collected at randomisation and sent to central laboratories for testing. Serum was tested 157 for SARS-CoV-2 nucleocapsid antigen, anti-SARS-CoV-2 spike antibodies, and anti-158 SARS-CoV-2 nucleocapsid antibodies using Roche Elecsys assays (Roche Diagnostics, 159 Basel, Switzerland). Patients were classified as having high- or low- serum nucleocapsid 160 antigen using the trial population median value, and as positive or negative for anti-spike 161 and anti-nucleocapsid antibodies using manufacturer defined thresholds (testing was 162 retrospective, so results were not available to the patient's medical team). Nose swabs

Sotrovimab for COVID-19

163 were tested for SARS-CoV-2 RNA using TagPath COVID-19 RT-PCR (Thermo Fisher 164 Scientific, Massachusetts, US). Samples with sufficient viral RNA were sequenced using the ONT Midnight protocol (Oxford Nanopore Technologies, Oxford, UK).²⁹ Sequence 165 data were used to detect spike protein mutations associated with >5-fold reduction in 166 167 sotrovimab neutralisation, which were identified from the sotrovimab summary of product 168 characteristics and the Stanford University Coronavirus Antiviral and Resistance Database.³⁰ Further details of laboratory analyses and the resistance mutations included 169 170 are in the appendix (pp33-34, 188-203).

Follow-up nose swabs were collected on day 3 and day 5 (counting the day of randomisation as day 1). These were analysed in the same manner as the baseline swab described above.

174 An online follow-up form was completed when participants were discharged, had died or 175 at 28 days after randomisation, whichever occurred earliest (appendix pp48-56). 176 Information was recorded on adherence to allocated study treatment, receipt of other 177 COVID-19 treatments, duration of admission, receipt of respiratory or renal support, major 178 safety outcomes, and vital status (including cause of death). In addition, routine 179 healthcare and registry data were obtained, including information on vital status (with date 180 and cause of death), discharge from hospital, receipt of respiratory support, or renal 181 replacement therapy.

182 Outcomes

Outcomes were assessed at 28 days after randomisation, with further analyses specified
at 6 months (not reported here). The primary outcome was all-cause mortality at 28 days.

Sotrovimab for COVID-19

185 Secondary outcomes were time to discharge from hospital, and, among patients not on 186 invasive mechanical ventilation at randomisation, invasive mechanical ventilation 187 (including extra-corporal membrane oxygenation) or death. Prespecified subsidiary 188 clinical outcomes were use of invasive or non-invasive ventilation (including high-flow 189 nasal oxygen) among patients not on any ventilation at randomisation, and use of renal 190 dialysis or haemofiltration. Prespecified safety outcomes were cause-specific mortality, 191 major cardiac arrhythmia, thrombotic and major bleeding events, non-SARS-CoV-2 192 infections, hyper/hypoglycaemia, seizures, acute liver or kidney injury, and infusion 193 reactions to sotrovimab. Virological outcomes were viral RNA copy number in nose swabs 194 taken at day 3 and day 5, and the frequency of detection of resistance mutations. 195 Information on suspected serious adverse reactions was collected in an expedited fashion 196 to comply with regulatory requirements. Details of the methods used to ascertain and 197 derive outcomes are provided in the appendix (pp164).

198 Statistical Analysis

199 For all outcomes, intention-to-treat analyses compared patients randomly allocated 200 sotrovimab with patients randomly allocated usual care. For the primary outcome of 28-201 day mortality, the hazard ratio from a Cox model with adjustment for age in three 202 categories (<70 years, 70-79 years, and 80 years or older) and ventilation status at 203 randomisation in four categories (no oxygen, simple oxygen only, non-invasive ventilation 204 and invasive mechanical ventilation) was used to estimate the mortality rate ratio. We 205 constructed Kaplan-Meier survival curves to display cumulative mortality over the 28-day 206 period (starting on the day of randomisation and ending 28 days later). We used the same 207 Cox regression method to analyse time to hospital discharge and successful cessation of

Sotrovimab for COVID-19

invasive mechanical ventilation, with patients who died in hospital right-censored on day209 29.

210 Median time to discharge was derived from Kaplan-Meier estimates. For the composite 211 secondary outcome of progression to invasive mechanical ventilation or death within 28 212 days, and the subsidiary clinical outcomes of receipt of ventilation and use of 213 haemodialysis or haemofiltration, the precise dates were not available and a log-binomial 214 regression model was used to estimate the risk ratio adjusted for age and ventilation 215 status (in the same categories as listed above). Estimates of rate and risk ratios are shown with 95% confidence intervals. SARS-CoV-2 viral RNA levels in nose-swabs were 216 217 estimated with analysis of covariance (ANCOVA) using the log transformed values after 218 adjustment for each participant's baseline value, age and level of respiratory support at 219 randomisation. Missing baseline and follow-up values of SARS-CoV-2 viral RNA levels 220 were estimated using multiple imputation, with 20 replicate sets and combination of results across sets using the methods of Rubin.31 221

222 When the sotrovimab comparison was added to the protocol in December 2021, there 223 was insufficient information to decide if anti-S or anti-N antibody status should define the 224 primary analysis population, or if serum antigen status would be preferable. The statistical 225 analysis plan stated that this would be determined at a future date (but prior to unblinding 226 of the investigator team). Shortly after recruitment closed, but before the investigators 227 were unblinded, high-antigen patients were selected as the primary analysis population because of low numbers of seronegative patients in the trial population and because 228 229 antigen positivity best predicted mortality (described in the updated statistical analysis

Sotrovimab for COVID-19

230 plan, appendix pp154-156). It was hypothesised that any beneficial effect of sotrovimab 231 would be larger among high-antigen patients and may be negligible in low-antigen 232 patients. Formal hypothesis-testing of the effect of allocation to sotrovimab on 28-day 233 mortality was to be done firstly in high-antigen participants (the primary analysis 234 population), and was to be done among all randomised participants only if a reduction in 235 mortality in high-antigen patients was seen at 2p<0.05. Formal testing of secondary 236 outcomes was only to be done if a mortality reduction among all participants was seen at 237 2p<0.05. A prespecified comparison of the effects of allocation to sotrovimab on 28-day 238 mortality in high-antigen versus low-antigen participants was done by performing a test 239 for heterogeneity. Tests for heterogeneity according to other baseline characteristics were 240 also prespecified (age, sex, ethnicity, level of respiratory support, days since symptom 241 onset. of corticosteroids. anti-SARS-CoV-2 antibody use status, and 242 immunosuppression).

243 Because trial recruitment and event rates during the COVID-19 pandemic were 244 unpredictable, RECOVERY treatment comparisons have not had a predetermined 245 sample size. With high levels of recruitment, the intention would have been to continue 246 until enough primary outcomes had accrued for a 90% power to detect a proportional risk 247 reduction of 20% at 2p=0.01 (approximately 5,500 participants if mortality were 20% 248 without treatment). Following the initial wave of Omicron infection in the UK in early 2022, 249 the number of patients hospitalised with COVID-19 pneumonia reduced substantially in the UK, as did trial recruitment. The trial comparison closed on 31st March 2024 when 250 251 funding for the trial ended.

Sotrovimab for COVID-19

The full database is held by the study team which collected the data from study sites and performed the analyses at the Nuffield Department of Population Health, University of Oxford (Oxford, UK). Analyses were performed using SAS version 9.4 and R version 4.0.3. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

257 Role of the funding source

Neither the study funders, nor the manufacturers of sotrovimab, had any role in study design, data collection, data analysis, or writing of the report. GSK and Vir Biotechnology supported the study through supply of sotrovimab and reviewed the draft publication for scientific consistency and completeness. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

264 **RESULTS**

265 Between 4 January 2022 and 19 March 2024, 1723/1824 (94%) patients enrolled into the 266 RECOVERY trial at sites participating in the sotrovimab comparison were eligible and 267 agreed to be included in sotrovimab comparison, of whom 1448 (84%) were recruited in 2022. 828 were allocated sotrovimab and 895 were allocated usual care without 268 269 sotrovimab (figure 1). The mean age of study participants was 70.7 years (SD 14.8), 1389 270 (81%) had received a COVID-19 vaccine, and 414 (24%) were severely 271 immunocompromised in the opinion of the managing clinician (table 1, appendix pp59-272 60). At randomisation, the median time since symptom onset was 6 days (IQR 3-11 days), 273 1467 (85%) were receiving oxygen or ventilatory support, and 628 (36%) were receiving

Sotrovimab for COVID-19

remdesivir. Serological results were available for 1439 (84%) of patients, among whom
720 (50%) had a serum concentration above the median ('high-antigen'), 1179 (82%)
were anti-SARS-CoV-2 spike antibody positive, and 454 (32%) were anti-SARS-CoV-2
nucleocapsid antibody positive (table 1).

The follow-up form was completed for 1710 (99%) patients, and among them 767/820 (94%) allocated sotrovimab received the treatment, compared to 14/890 (2%) allocated usual care (figure 1). Use of other treatments for COVID-19 was similar among patients allocated sotrovimab and those allocated usual care (appendix p61). Primary and secondary outcome data are known for more than 99% of randomly assigned patients.

In patients who had high-antigen at baseline, allocation to sotrovimab was associated 283 284 with a reduction in the primary outcome of 28-day mortality compared with usual care 285 alone: 82/355 (23%) patients in the sotrovimab group died versus 106/365 (29%) patients 286 in the usual care group (rate ratio 0.75; 95% CI 0.56-0.99; p=0.046; table 2, figure 2a, 287 figure 3). Among all patients randomised (including those with high, low, or unknown 288 baseline antigen status), there was no significant difference in the primary outcome of 28dav mortality between the two randomised groups: 177/828 (21%) patients in the 289 290 sotrovimab group died versus 201/895 (22%) patients in the usual care group (rate ratio 291 0.95; 95% CI 0.77-1.16; p=0.60; figure 2b, figure 3, appendix p62). There was no 292 evidence that the proportional effects on mortality differed among any pre-specified 293 subgroups among high-antigen patients, or among all patients (figure 4, appendix pp67-294 69).

Sotrovimab for COVID-19

Among high-antigen patients, discharge alive within 28 days did not differ between those
allocated sotrovimab compared to usual care (66% versus 58%; rate ratio 1.12, 95% CI
0.93-1.34; median time to being discharged alive 13 days versus 16 days) (table 2, figure
3). There was also no difference in this outcome among the overall study population (68%
versus 68%; rate ratio 0.96, 95% CI 0.85-1.08; median time to being discharged alive 11
days versus 11 days) (figure 3, appendix p62).

Among high-antigen patients not on invasive ventilation at baseline, allocation to sotrovimab was not associated with a lower risk of progressing to the composite secondary outcome of invasive ventilation or death (24% versus 29%, risk ratio 0.82, 95% CI 0.64-1.03) (table 2, figure 3). There was also no difference in this outcome among the overall study population (23% versus 23%, risk ratio 0.98, 95% CI 0.84 to 1.16) (figure 3, appendix p62).

We found no evidence of any difference between groups in the prespecified subsidiary outcomes among high-antigen patients, or among all patients, including in use of ventilation in those not on ventilation at baseline, successful cessation of ventilation, or use of renal replacement therapy (table 2, appendix p62).

1479/1723 (86%) of patients had at least one nose swab available for analysis. Allocation to sotrovimab was not associated with a lower baseline-adjusted viral RNA copy number in nose swabs taken on day 3 or day 5 (table 2). 1119 (65%) patients had at least one successfully sequenced sample, and of those with at least one high quality sample (\geq 90% genome coverage), 1021/1026 (>99%) were identified as Omicron variants (primarily BA.1, BA.2, BA.5, and XBB). 1655/1723 (96%) patients were recruited before November

Sotrovimab for COVID-19

2023, and of these 14/1026 (1%) with a sequenced sample had a sotrovimab resistance mutation detected at baseline, and 3/692 (<0.5%) with sequenced baseline and follow-up samples had a new sotrovimab resistance mutation arising after trial entry, two of whom had received sotrovimab (relevant mutations are listed in appendix p34). Among the 68/1723 (4%) patients recruited after 1 November 2023, 14/35 (40%) with a sequenced sample were infected with BA.2.86 variants, which are known to contain the K356T spike mutation associated with high-level sotrovimab resistance.

324 Infusion reactions were reported for 12/781 (2%) patients receiving sotrovimab. Of these, nine were mild (no intervention required), two moderate (antihistamines or steroids 325 326 required) and one severe (adrenaline required). Two serious adverse reactions to 327 sotrovimab were reported, both of which were infusion reactions included above, one of 328 which was in a patient with suspected anaphylaxis that resolved with treatment. We found 329 no difference between groups in other safety outcomes, including cause-specific mortality, 330 new cardiac arrhythmia, thrombosis, bleeding, non-coronavirus infections, hypo- or 331 hyper-glycaemia, seizures, acute kidney injury or liver injury (appendix pp63-64).

332 **DISCUSSION**

In this randomised trial including over 1700 patients with COVID-19 pneumonia, sotrovimab was associated with a reduction in 28-day mortality in those with a high serum nucleocapsid antigen concentration, although there was substantial uncertainty about the size of this apparent benefit (RR 0.75; 95% CI 0.56-0.99; p=0.046). An analysis of all patients, regardless of antigen concentration, did not show evidence of any benefit of treatment on 28-day mortality. By contrast with our previous study of monoclonal antibody

Sotrovimab for COVID-19

treatment in this setting, the current study was performed during a period of Omicron
 infection and widespread vaccination and natural immunity.⁴

341 The number of patients hospitalised with COVID-19 pneumonia fell dramatically after 342 vaccination was introduced and Omicron became dominant, so this comparison could not 343 provide results as definitive as those of the earlier RECOVERY casirivimab-imdevimab 344 comparison that recruited nearly 10,000 patients. However, the pattern of results from the 345 two RECOVERY mAb comparisons are similar, despite using different markers of 346 infection status to categorise patients. In both, a subset of patients with immune 347 responses that were not yet adequate to clear infection were at higher risk of death than 348 patients with more robust immune responses, and in that higher risk subset mAb therapy 349 reduced the risk of death. During the period this comparison was recruiting, SARS-CoV-350 2 infection in hospitalised patients was often an incidental finding or associated with non-351 respiratory illness, and the benefits of antiviral therapy in these patients may be limited. 352 In contrast, RECOVERY only included those with pneumonia thought to be related to 353 COVID-19 and in 81% of participants this had developed despite previous COVID-19 354 vaccination. In keeping with this, over 80% of those with known serostatus had anti-spike 355 antibodies, although two-thirds were anti-nucleocapsid antibody negative, indicating that 356 this was likely their first SARS-CoV-2 infection.³² The risk of death from COVID-19 was 357 high. 28-day mortality was 22% in those allocated usual care, similar to the risk among 358 RECOVERY patients recruited in the pre-Omicron era. Since the emergence of Omicron, 359 immunocompromised patients have made up a higher proportion of those hospitalised 360 and dying from COVID-19 pneumonia, and in keeping with this one-quarter of the 361 RECOVERY patients were considered severely immunocompromised.33

Sotrovimab for COVID-19

362 The benefit of mAb therapy in SARS-CoV-2 antibody negative hospitalised patients was 363 established in previous trials, but this approach to targeting therapy was necessarily short-lived in the context of increasing population immunity.^{4–6} In contrast, targeting 364 365 therapy on the basis of antigenaemia remains possible for future hospitalised patients. 366 and is practical using existing commercial assays (the one used in RECOVERY takes 20 367 minutes on a widely available automated clinical laboratory platform). The ACTIV-3/TICO 368 platform trial is the only previous trial of mAb therapy reporting outcomes by baseline 369 blood antigen status, and this evaluated four mAb therapies, although three of these were stopped early for futility.^{6,14,34} In the single comparison not stopped early, 1417 370 371 hospitalised patients were randomised to receive tixagevimab-cilgavimab or placebo. 372 Among patients with blood antigen above the median value, 90-day mortality was 43/340 373 (13%) in those allocated mAb versus 51/342 (15%) in those allocated placebo (hazard 374 ratio 0.84; 95%CI 0.56-1.26; p=0.39); although inconclusive the point estimate is 375 consistent with this RECOVERY result that is based on twice as many events.

376 Neutralising mAbs emerged as powerful therapeutic tools during the pandemic, which 377 highlighted their potential uses but also their limitations, particularly the loss of activity 378 against emergent viral variants. Despite retaining potentially valuable neutralising activity 379 against Omicron variants prevalent in 2022-23, high-level sotrovimab resistance was 380 identified in Omicron lineages that became globally dominant in early 2024, including 381 BA.2.86 and JN.1, and it is no longer likely to have useful activity against currently 382 circulating variants that have retained sotrovimab resistance mutations.³⁵ The loss of all 383 anti-SARS-CoV-2 mAbs that were in clinical use has led to new approaches to mAb 384 therapy, including attempts to target more highly conserved viral epitopes, new antibody

Sotrovimab for COVID-19

fragments or formulations that may have better potency or tissue penetration, and antibody cocktails or poly-specific antibodies that may be more robust to viral evolution.³⁶ The results of this comparison suggest that if new mAb therapies can be developed that effectively neutralise current and future SARS-CoV-2 variants then they could continue to benefit hospitalised patients.

390 Most patients in the RECOVERY sotrovimab comparison were recruited in 2022, and, 391 other than lineage-defining Omicron mutations, there were few important sotrovimab 392 resistance mutations identified in either baseline or follow-up samples. Because of 393 concerns about possible reduced sotrovimab activity against BA.1, a 1g dose was used 394 in RECOVERY rather than the 500mg dose tested previously, and this was well tolerated 395 with no new safety concerns. The lack of any measurable effect of sotrovimab on nasal 396 SARS-CoV-2 carriage by day 5 may be related to the early sampling timepoints used, as 397 even in seronegative patients treated with a well-matched mAb, a reduction in carriage of viral RNA is mainly apparent from day 7 onwards.⁵ In contrast to changes in viral RNA 398 399 carriage, a large reduction in culturable SARS-CoV-2 can be seen as early as 24 hours 400 after mAb therapy, but virological testing in RECOVERY did not extend to culture.³⁷

401 Strengths of this trial include that it was randomised, had broad eligibility criteria, and a 402 large sample size, being the second largest trial of mAb therapy performed in patients 403 hospitalised with COVID-19. It includes baseline characterisation of markers of SARS-404 CoV-2 immune status and infection, and more than 99% of patients were followed up for 405 the primary and secondary outcomes. The study has some limitations: the use of serum 406 antigen to define the primary analysis population was prespecified, but this is a novel 407 therapeutic biomarker and there is little existing evidence to support the threshold used

Sotrovimab for COVID-19

408 to classify patients. The distribution of serum antigen in our population was unimodal with 409 no natural cut-point, so other thresholds could have been selected. In a larger trial it may 410 have been possible to retrospectively identify an optimal antigen threshold, but this kind 411 of sensitivity analysis would not be robust in our study given the limited number of 412 outcome events. Use of other antiviral treatments was relatively common, with remdesivir 413 received by one-third of patients, and it is possible that sotrovimab would have had a 414 greater effect in the absence of other antivirals. The RECOVERY trial is open label, so 415 participants and local hospital staff were aware of the assigned treatment. This could 416 potentially have affected clinical management or the recording of some trial outcomes. 417 although we found no evidence that management differed by treatment allocation 418 (appendix p61), and the primary and secondary outcomes are unambiguous and were 419 ascertained without bias through linkage to routine health records. Although virological 420 outcomes were included, this did not include viral culture, and no information on 421 radiological or physiological outcomes was collected. The RECOVERY trial only studied 422 patients who had been hospitalised with COVID-19 and, therefore, is not able to provide 423 any evidence on the safety and efficacy of treatments in other patient groups, such as 424 those with early infection.

In summary, the results of this randomised trial suggest that some hospitalised COVID-19 patients at high risk of death could continue to benefit from mAb therapy, and that antigen testing could help to identify these patients. Although no currently available mAbs have satisfactory activity against current SARS-Cov-2 variants, these results should inform future mAb evaluation and treatment strategies.

Sotrovimab for COVID-19

430 **Contributors**

431 This manuscript was initially drafted by LP, RH, PWH and MJL, further developed by the 432 Writing Committee, and approved by all members of the trial steering committee. NS, 433 JRE, PWH, MJL, RH and LP had access to the study data. NS and JRE accessed and 434 verified the data. JRE did the statistical analysis. PWH and MJL vouch for the data and 435 analyses, and for the fidelity of this report to the study protocol and data analysis plan, 436 and had final responsibility for the decision to submit for publication. PWH, NS, JRE, JKB, MB, SNF, TJ, EJ, KJ, MK, WSL, AMo, AMuk, AMum, KR, GT, MM, RH, and MJL designed 437 438 the trial and study protocol. MM, MC, G P-A, LP, RS, DG, GC, FH, JM-C, PD, PH, JU, 439 NE, JM, SB, the Data Linkage team at the RECOVERY Coordinating Centre, and the 440 Health Records and Local Clinical Centre staff listed in the appendix collected the data. 441 All authors contributed to data interpretation and critical review and revision of the 442 manuscript.

Sotrovimab for COVID-19

444 Writing Committee (on behalf of the RECOVERY Collaborative Group):

Peter W Horby*, Jonathan R Emberson*, Leon Peto*, Natalie Staplin, Mark Campbell,
Guilherme Pessoa-Amorim, Richard Stewart, Dipansu Ghosh, Graham Cooke, Natalie
Blencowe, Jeronimo Moreno-Cuesta, Purav Desai, Paul Hine, Jonathan Underwood,
Nicholas Easom, Jaydip Majumdar, Sanjay Bhagani, J Kenneth Baillie, Maya Buch, Saul
N Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim,

- 450 Alan Montgomery, Aparna Mukherjee, Andrew Mumford, Kathryn Rowan, Guy Thwaites,
- 451 Marion Mafham[†], Richard Haynes[†], Martin J Landray[†].
- 452 *,[†] equal contribution

453 Data Monitoring Committee

- 454 Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo,
- 455 Mohammed Munavvar, Janet Wittes.

456 **Declaration of interests**

457 The authors have no conflict of interest or financial relationships relevant to the submitted 458 work to disclose. No form of payment was given to anyone to produce the manuscript. All 459 authors have completed and submitted the ICMJE Form for Disclosure of Potential 460 Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or 461 indirectly from industry (see https://www.ndph.ox.ac.uk/files/about/ndph-independence-462 463 of-research-policy-jun-20.pdfhttps://www.ctsu.ox.ac.uk/about/ctsu honoraria 25june14-464 1.pdf).

Sotrovimab for COVID-19

465 Data sharing

466 The protocol, consent form, statistical analysis plan, definition & derivation of clinical 467 characteristics & outcomes, training materials, regulatory documents, and other relevant 468 study materials are available online at www.recoverytrial.net. As described in the protocol, 469 the Trial Steering Committee will facilitate the use of the study data and approval will not 470 be unreasonably withheld. Deidentified participant data will be made available to bona 471 fide researchers registered with an appropriate institution within 3 months of publication. 472 However, the Steering Committee will need to be satisfied that any proposed publication 473 is of high quality, honours the commitments made to the study participants in the consent 474 documentation and ethical approvals, and is compliant with relevant legal and regulatory 475 requirements (e.g. relating to data protection and privacy). The Steering Committee will 476 have the right to review and comment on any draft manuscripts prior to publication. Data 477 will be made available in line with the policy and procedures described at: 478 https://www.ndph.ox.ac.uk/data-access. Those wishing to request access should 479 complete the form at

- 480 <u>https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx</u>
- 481 and e-mailed to: <u>data.access@ndph.ox.ac.uk</u>
- 482

483 Acknowledgements

Above all, we would like to thank the patients who participated in this trial. We would also like to thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at NHS hospital organisations across the whole of the UK,

Sotrovimab for COVID-19

supported by staff at the National Institute of Health and Care Research (NIHR) Clinical
Research Network, NHS DigiTrials, UK Health Security Agency, Department of Health &
Social Care, the Intensive Care National Audit & Research Centre, Public Health
Scotland, National Records Service of Scotland, the Secure Anonymised Information
Linkage (SAIL) at University of Swansea, and the NHS in England, Scotland, Wales and
Northern Ireland.

The RECOVERY trial was supported by grants to the University of Oxford from UK 493 494 Research and Innovation (UKRI) and NIHR (MC PC 19056), and by core funding 495 provided by the NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill 496 and Melinda Gates Foundation, the Foreign, Commonwealth and Development Office, 497 Health Data Research UK, the Medical Research Council, the NIHR Health Protection 498 Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. 499 TJ is supported by grants from the UK Medical Research Council (MC UU 0002/14 and 500 MC UU 00040/03). WSL is supported by core funding provided by NIHR Nottingham 501 Biomedical Research Centre. JU is supported by a UK Medical Research Council grant 502 (MR/T023791/1).

503 The views expressed in this publication are those of the authors and not necessarily those 504 of the NHS, the NIHR, or the UK Department of Health and Social Care.

Sotrovimab for COVID-19

506 **References**

Gupta A, Gonzalez-Rojas Y, Juarez E, *et al.* Effect of Sotrovimab on
 Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A
 Randomized Clinical Trial. *JAMA* 2022; **327**: 1236–46.

510 2 Weinreich DM, Sivapalasingam S, Norton T, *et al.* REGEN-COV Antibody 511 Combination and Outcomes in Outpatients with Covid-19. *N Engl J Med* 2021; **385**: e81.

Montgomery H, Hobbs FDR, Padilla F, *et al.* Efficacy and safety of intramuscular
 administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19
 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Respir Med* 2022; **10**: 985–96.

516 4 RECOVERY Collaborative Group. Casirivimab and imdevimab in patients 517 admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-518 label, platform trial. *Lancet Lond Engl* 2022; **399**: 665–76.

519 5 Somersan-Karakaya S, Mylonakis E, Menon VP, *et al.* Casirivimab and 520 Imdevimab for the Treatment of Hospitalized Patients With COVID-19. *J Infect Dis* 521 2022; **227**: 23–34.

6 ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. *Lancet Respir Med* 2022; **10**: 972–84.

525 7 Iketani S, Ho DD. SARS-CoV-2 resistance to monoclonal antibodies and small-526 molecule drugs. *Cell Chem Biol* 2024; **31**: 632–57.

527 8 Cox M, Peacock TP, Harvey WT, *et al.* SARS-CoV-2 variant evasion of 528 monoclonal antibodies based on in vitro studies. *Nat Rev Microbiol* 2023; **21**: 112–24.

529 9 Cao Y, Wang J, Jian F, *et al.* Omicron escapes the majority of existing SARS-530 CoV-2 neutralizing antibodies. *Nature* 2022; **602**: 657–63.

531 10 Park Y-J, Pinto D, Walls AC, *et al.* Imprinted antibody responses against SARS532 CoV-2 Omicron sublineages. *Science* 2022; **378**: 619–27.

533 11 Wu MY, Carr EJ, Harvey R, *et al.* WHO's Therapeutics and COVID-19 Living
534 Guideline on mAbs needs to be reassessed. *The Lancet* 2022; **0**. DOI:10.1016/S0140535 6736(22)01938-9.

Addetia A, Piccoli L, Case JB, *et al.* Neutralization, effector function and immune
 imprinting of Omicron variants. *Nature* 2023; **621**: 592–601.

538 13 Planas D, Saunders N, Maes P, *et al.* Considerable escape of SARS-CoV-2
539 Omicron to antibody neutralization. *Nature* 2022; **602**: 671–5.

Sotrovimab for COVID-19

ACTIV-3/TICO Bamlanivimab Study Group*. Responses to a Neutralizing
Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline
Antibody and Antigen Levels : A Randomized Controlled Trial. *Ann Intern Med* 2021;
published online Dec 21. DOI:10.7326/M21-3507.

544 15 Wang H, Hogan CA, Verghese M, *et al.* SARS-CoV-2 Nucleocapsid Plasma 545 Antigen for Diagnosis and Monitoring of COVID-19. *Clin Chem* 2021; : hvab216.

546 16 Favresse J, Bayart J-L, David C, *et al.* Serum SARS-CoV-2 Antigens for the 547 Determination of COVID-19 Severity. *Viruses* 2022; **14**: 1653.

Jensen TO, Murray TA, Grandits GA, *et al.* Early trajectories of virological and
immunological biomarkers and clinical outcomes in patients admitted to hospital for
COVID-19: an international, prospective cohort study. *Lancet Microbe* 2024; **5**: e559–
69.

18 RECOVERY Collaborative Group, Horby P, Lim WS, *et al.* Dexamethasone in
 Hospitalized Patients with Covid-19. *N Engl J Med* 2021; **384**: 693–704.

19 RECOVERY Collaborative Group, Horby P, Mafham M, *et al.* Effect of
Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 2020; **383**:
2030–40.

RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to
 hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform
 trial. *Lancet Lond Engl* 2020; **396**: 1345–52.

RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital
 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
 Lancet Lond Engl 2021; **397**: 605–12.

563 22 RECOVERY Collaborative Group. Convalescent plasma in patients admitted to
 564 hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform
 565 trial. *Lancet Lond Engl* 2021; **397**: 2049–59.

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital
with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet Lond Engl* 2021; **397**: 1637–45.

569 24 RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with 570 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and 571 updated meta-analysis. *Lancet Lond Engl* 2022; **400**: 359–68.

572 25 RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with 573 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 574 *Lond Engl* 2021; : S0140-6736(21)01825-0.

Sotrovimab for COVID-19

575 26 RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with 576 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*

577 *Respir Med* 2021; **9**: 1419–26.

578 27 RECOVERY Collaborative Group. Higher dose corticosteroids in patients

admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory

support (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet Lond Engl* 2023; : S0140-6736(23)00510-X.

582 28 RECOVERY Collaborative Group. Empagliflozin in patients admitted to hospital
583 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
584 Lancet Diabetes Endocrinol 2023; **11**: 905–14.

Constantinides B, Webster H, Gentry J, *et al.* Rapid turnaround multiplex
 sequencing of SARS-CoV-2: comparing tiling amplicon protocol performance. *medRxiv* 2022; : 2021.12.28.21268461.

588 30 Tzou PL, Tao K, Pond SLK, Shafer RW. Coronavirus Resistance Database 589 (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, 590 and plasma from vaccinated persons. *PloS One* 2022; **17**: e0261045.

S1 Rubin, D. Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons,Inc., 1987.

593 32 Torres Ortiz A, Fenn Torrente F, Twigg A, *et al.* The influence of time on the 594 sensitivity of SARS-CoV-2 serological testing. *Sci Rep* 2022; **12**: 10517.

Singson JRC, Kirley PD, Pham H, *et al.* Factors Associated with Severe
Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 - COVIDNET, 10 States, March 2020-February 2022. *MMWR Morb Mortal Wkly Rep* 2022; 71:
878–84.

ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group.
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and
BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised
controlled trial. *Lancet Infect Dis* 2022; **22**: 622–35.

60335Focosi D, Casadevall A, Franchini M, Maggi F. Sotrovimab: A Review of Its604Efficacy against SARS-CoV-2 Variants. Viruses 2024; 16: 217.

605 36 Winiger RR, Perez L. Therapeutic antibodies and alternative formats against 606 SARS-CoV-2. *Antiviral Res* 2024; **223**: 105820.

Boucau J, Chew KW, Choudhary MC, *et al.* Monoclonal antibody treatment
drives rapid culture conversion in SARS-CoV-2 infection. *Cell Rep Med* 2022; 3:
100678.

Sotrovimab for COVID-19

611 **Table 1: Baseline characteristics**

	High-antigen	patients	All patients	
	Sotrovimab (n=355)	Usual care (n=365)	Sotrovimab (n=828)	Usual care (n=895)
Age, years	72.5 (13.3)	72.1 (13.7)	70.9 (14.2)	70.4 (15.4)
<70	123 (35%)	141 (39%)	342 (41%)	369 (41%)
≥70 to <80	123 (35%)	121 (33%)	251 (30%)	272 (30%)
≥80	109 (31%)	103 (28%)	235 (28%)	254 (28%)
Sex				
Male	218 (61%)	226 (62%)	490 (59%)	543 (61%)
Female	137 (39%)	139 (38%)	338 (41%)	352 (39%)
Ethnicity				
White	301 (85%)	333 (91%)	706 (85%)	779 (87%)
Black, Asian, and minority ethnic	32 (9%)	16 (4%)	64 (8%)	65 (7%)
Unknown	22 (6%)	16 (4%)	58 (7%)	51 (6%)
Number of days since symptom onset	6 (3-11)	6 (3-12)	6 (3-11)	6 (3-11)
Number of days since admission to hospital	2 (1-5)	2 (1-5)	2 (1-5)	2 (1-5)
Respiratory support received				
None	43 (12%)	54 (15%)	119 (14%)	137 (15%)
Simple oxygen	226 (64%)	213 (58%)	512 (62%)	557 (62%)
Non-invasive ventilation	71 (20%)	87 (24%)	168 (20%)	169 (19%)
Invasive mechanical ventilation	15 (4%)	11 (3%)	29 (4%)	32 (4%)
Previous diseases				
Diabetes	107 (30%)	84 (23%)	249 (30%)	219 (24%)
Heart disease	119 (34%)	113 (31%)	259 (31%)	272 (30%)
Chronic lung disease	123 (35%)	128 (35%)	327 (39%)	325 (36%)
Tuberculosis	0 (0%)	1 (<0.5%)	2 (<0.5%)	4 (<0.5%)
HIV	3 (1%)	1 (<0.5%)	6 (1%)	5 (1%)
Severe liver disease *	6 (2%)	3 (1%)	19 (2%)	16 (2%)
Severe kidney impairment †	45 (13%)	41 (11%)	84 (10%)	74 (8%)
Any of the above	242 (68%)	237 (65%)	578 (70%)	602 (67%)
Severely immunocompromised ‡	112 (32%)	112 (31%)	206 (25%)	208 (23%)
Received a COVID-19 vaccine	296 (83%)	292 (80%)	675 (82%)	714 (80%)
Use of other treatments				
Corticosteroids §	329 (93%)	334 (92%)	755 (91%)	801 (89%)
Remdesivir	144 (41%)	128 (35%)	315 (38%)	313 (35%)
Tocilizumab	66 (19%)	60 (16%)	144 (17%)	137 (15%)
Plan to use tocilizumab within the next 24 hours	28 (8%)	33 (9%)	48 (6%)	67 (7%)
Viral load in baseline nose swab				
Median level (log viral copies per ml)	6.1 (4.6-7.0)	6.1 (5.0-7.2)	5.6 (3.7-6.7)	5.6 (3.9-6.8)
Antigen status				
High	355 (100%)	365 (100%)	355 (43%)	365 (41%)
Low	0 (0%)	0 (0%)	339 (41%)	378 (42%)
Unknown	0 (0%)	0 (0%)	134 (16%)	152 (17%)
Serostatus (anti N)				
Positive	62 (17%)	76 (21%)	214 (26%)	240 (27%)
Negative	293 (83%)	289 (79%)	481 (58%)	504 (56%)
Unknown	0 (0%)	0 (0%)	133 (16%)	151 (17%)
Serostatus (anti S)				
Positive	252 (71%)	262 (72%)	569 (69%)	610 (68%)
Negative	103 (29%)	103 (28%)	126 (15%)	133 (15%)
Unknown	0 (0%)	0 (0%)	133 (16%)	152 (17%)

Data are mean (SD), n (%), or median (IQR). 4 pregnant women were randomised. * Defined as requiring ongoing specialist care. \dagger Defined as estimated glomerular filtration rate <30 mL/min per 1.73 m². \ddagger In the opinion of the managing clinician. § Including all those randomised into the comparison of high vs low dose steroids.

Sotrovimab for COVID-19

Table 2: Effect of allocation to sotrovimab on key study outcomes in patients with

614 among high-antigen levels

	Sotrovimab (n=355)	Usual care (n=365)	RR (95% CI) or mean difference	p-value
Primary outcome				
28-day mortality	82 (23%)	106 (29%)	0.75 (0.56-0.99)	0.046
Secondary outcomes				
Median (IQR) time to being discharged alive, days	13 (7 to >28)	16 (7 to >28)		
Discharged from hospital within 28 days	236 (66%)	226 (62%)	1.12 (0.93-1.34)	
Receipt of invasive mechanical ventilation or death*	82/340 (24%)	102/354 (29%)	0.82 (0.64-1.03)	
Invasive mechanical ventilation	14/340 (4%)	11/354 (3%)	1.71 (0.81-3.61)	
Death	74/340 (22%)	100/354 (28%)	0.74 (0.58-0.95)	
Subsidiary clinical outcomes				
Use of ventilation†	41/269 (15%)	41/267 (15%)	0.97 (0.66-1.44)	
Non-invasive ventilation	40/269 (15%)	41/267 (15%)	0.95 (0.64-1.41)	
Invasive mechanical ventilation	6/269 (2%)	3/267 (1%)	1.82 (0.47-7.11)	
Successful cessation of invasive mechanical ventilation ‡	5/15 (33%)	3/11 (27%)	1.07 (0.25-4.65)	
Use of haemodialysis or haemofiltration §	12/347 (3%)	6/356 (2%)	1.97 (0.77-5.06)	
Virological outcomes				
Baseline-adjusted viral load (log copies/ml) on day 3	4.89 (0.10)	4.94 (0.10)	-0.05 (-0.32, 0.23)	
Baseline-adjusted viral load (log copies/ml) on day 5	4.26 (0.11)	4.35 (0.10)	-0.09 (-0.38, 0.20)	

Data are n (%) or n/N (%), unless otherwise indicated. RR=rate ratio for the outcomes of 28-day mortality and hospital discharge, risk ratio for other clinical outcomes, and mean difference for virological outcomes. CI=confidence interval. Estimates of the RR or mean difference and their 95% CIs are adjusted for age in three categories (<70 years, 70-79 years, and 80 years or older) and ventilation status at randomisation in four categories (none, simple oxygen, non-invasive ventilation, and invasive mechanical ventilation). P-values are not shown for the secondary, subsidiary or virological outcomes because the hierarchical testing strategy pre-specified in the statistical analysis plan stated that such tests would only be performed if null hypothesis for the primary outcome of 28-day mortality was rejected in both the antigen positive subgroup *and* in the whole population * Excluding patients receiving invasive mechanical ventilation at randomisation. \$ Excluding patients receiving invasive receiving invasive mechanical ventilation at randomisation. S Excluding patients receiving receiving receiving invasive mechanical ventilation at randomisation. S Excluding patients receiving receiving receiving invasive mechanical ventilation at randomisation.

Sotrovimab for COVID-19

616 Figure 1: Trial profile

- 617 ITT=intention to treat. Drug unavailability and unsuitability are not mutually exclusive.
- ⁶¹⁸ *Number recruited overall at all sites participating in the sotrovimab comparison during
- 619 period that this comparison was open.
- Figure 2: Effect of allocation to sotrovimab on 28-day mortality in (a) high-antigen
- 621 versus low-antigen patients, and (b) all patients
- 622 Figure 3: Primary and secondary outcomes, overall and by baseline antigen

623 status. Subgroup-specific RR estimates are represented by squares (with areas of the

squares proportional to the amount of statistical information) and the lines through them

625 correspond to the 95% CIs. Open squares represent participants with unknown status,

626 solid squares represent participants with known status. The tests for heterogeneity

627 compare the log RRs in high-antigen versus low-antigen patients (i.e. excluding those

628 with unknown antigen status). All participants are included in the overall summary

diamonds. RR=risk ratio for the composite outcome of invasive mechanical ventilation

630 or death, and rate ratio for the other outcomes.

631 Figure 4: Effect of allocation to sotrovimab on 28-day mortality by baseline

632 characteristics in high-antigen participants. Subgroup-specific rate ratio estimates

are represented by squares (with areas of the squares proportional to the amount of

634 statistical information) and the lines through them correspond to the 95% CIs. The

635 ethnicity, days since onset and use of corticosteroids subgroups exclude those with

636 missing data, but these patients are included in the overall summary diamond.



Figure 2: Effect of allocation to sotrovimab on 28–day mortality in: a) participants with high vs low antigen levels; and b) all participants



Figure 3: Primary and secondary outcomes, overall and by baseline antigen status

Outcome, subgroup	Sotrovimab	Usual care		RR (95% CI
Death within 28 days (χ_1^2	= 2.8; p=0.09)			
High antigen	82/355 (23%)	106/365 (29%)	← ∎	- 0.75 (0.56–0.99)
Low antigen	52/339 (15%)	56/378 (15%)		→ 1.12 (0.77–1.64)
Unknown status	43/134 (32%)	39/152 (26%)		□→ 1.37 (0.89–2.12)
All participants	177/828 (21%)	201/895 (22%)	<	0.95 (0.77–1.16)
Discharge alive from hos	spital (χ_1^2 =4.2; p=0.0	4)		
High antigen	236/355 (66%)	226/365 (62%)	_	1.12 (0.93–1.34)
Low antigen	248/339 (73%)	283/378 (75%)		- 0.86 (0.72–1.02)
Unknown status	79/134 (59%)	100/152 (66%)	O	0.89 (0.66–1.20)
All participants	563/828 (68%)	609/895 (68%)	<	0.96 (0.85–1.08)
Invasive mechanical ven	tilation or death (χ_1^2	=1.7; p=0.19)		
High antigen	82/340 (24%)	102/354 (29%)		- 0.82 (0.64–1.03)
Low antigen	55/333 (17%)	61/368 (17%)		1.07 (0.78–1.46)
Unknown status	47/126 (37%)	38/141 (27%)	-	> 1.30 (0.96-1.76)
All not on invasive mechanical ventilation at randomisation	184/799 (23%)	201/863 (23%)	<	0.98 (0.84–1.16)
			0.6 0.8	1 1.2 1.4 1.6
			Outcome less likely with sotrovimab	Outcome more likely with sotrovimab

Figure 4: Effect of allocation to sotrovimab on 28–day mortality in participants with high antigen levels, by other baseline characteristics

	Sotrovimab	Usual care		RR (95% CI)
Age, years (χ^2_1 = 0.2; p=0.66)				
<70	19/123 (15%)	27/141 (19%)		> 0.80 (0.44−1.44)
≥70 <80	30/123 (24%)	37/121 (31%)		0.79 (0.49–1.28)
≥80	33/109 (30%)	42/103 (41%)		0.68 (0.43–1.08)
Sex (χ ₁ ² =0.7; p=0.39)				
Men	54/218 (25%)	68/226 (30%)		0.82 (0.57–1.17)
Women	28/137 (20%)	38/139 (27%)	← ■	0.63 (0.39–1.03)
Ethnicity (χ_1^2 =0.6; p=0.42)				
White	69/301 (23%)	100/333 (30%)	B	0.71 (0.52–0.97)
Black, Asian and Minority Ethnic	6/32 (19%)	2/16 (12%)	←	> 1.39 (0.28–6.93)
Days since symptom onset (χ_1^2	= 0.1; p=0.73)			
≤7	43/209 (21%)	54/204 (26%)		0.72 (0.48–1.07)
>7	39/146 (27%)	52/161 (32%)		0.79 (0.52–1.20)
Respiratory support at random	isation (χ ₁ ² = 0.4; μ	p=0.55)		
None	4/43 (9%)	8/54 (15%)	<	> 0.61 (0.18–2.04)
Simple oxygen	45/226 (20%)	56/213 (26%)		0.74 (0.50–1.09)
Non-invasive ventilation	25/71 (35%)	36/87 (41%)		0.70 (0.42–1.18)
Invasive mechanical ventilation	8/15 (53%)	6/11 (55%)		> 1.18 (0.41−3.42)
Use of corticosteroids				
Yes	81/329 (25%)	102/334 (31%)		0.76 (0.57–1.02)
No	1/26 (4%)	4/31 (13%)		NE
Severely immunocompromised	l (χ²=0.0; p=0.97)			
Yes	31/112 (28%)	43/112 (38%)		0.73 (0.46–1.17)
No	51/243 (21%)	63/253 (25%)		0.74 (0.51–1.08)
All participants	82/355 (23%)	106/365 (29%)		0.75 (0.56–0.99) p=0.046
			0.4 0.0 0.0 1 1.2	1.4
			Sotrovimab Usual care better better	